We analyse three recent Patent Office decisions for guidance on medical technology patents following the High Court's judgment in Aristocrat.
We review the requirements to use experiments in Federal Court patent proceedings having regard to the recent decision in Sanofi v Amgen.
We consider the High Court’s unanimous judgment regarding whether a trade mark's reputation is relevant when deciding if it has been infringed.
We provide a summary of the Therapeutic Goods Amendment Act which introduces a wide range of amendments to the Therapeutic Goods Act.
We identify the key changes to the supply of medicines and poisons in NSW with the introduction of the Medicines, Poisons and Therapeutic Goods Act 2022.
We summarise the findings and recommendations of the recent independent report on fraud, non-compliance and overservicing in Medicare.
With the rise of ChatGPT, we consider how to harness the technology while ensuring the risks associated with it are mitigated.
We discuss the Federal Court's consideration of the proposed $300 million dollar settlement in the Johnson & Johnson representative class action regarding its transvaginal mesh products.
An update on the new accreditation scheme for cosmetic surgery following the Independent Review of the Regulation of Health Practitioners and Patient Safety Issues in Cosmetic Surgery.
We take a look at Australia's standing in the global biosimilars market and factors affecting the uptake of biosimilar medicines in Australia.